Purpose: Status epilepticus (SE) requires not only urgent symptomatic treatment with antiepileptic drugs but also rapid identification and treatment of its cause. This narrative review summarizes the most important advances in classification and treatment of SE. Method: Data sources included MEDLINE, EMBASE, ClinicalTrials.gov, and back tracking of references in pertinent studies, reviews, and books. Results: SE is now defined as "a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t1). It is a condition, which can have long-term consequences (after time point t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures." A new diagnostic classification system of SE introduces four axes: semiology, aetiology, EEG correlates, and age. For the acute treatment intravenous benzodiazepines (lorazepam, diazepam, clonazepam) and intramuscular midazolam appear as most effective treatments for early SE. In children, buccal or intranasal midazolam are useful alternatives. In established SE intravenous antiepileptic drugs (phenytoin, valproate, levetiracetam, phenobarbital, and lacosamide) are in use. Treatment options in refractory SE are intravenous anaesthetics; ketamine, magnesium, steroids and other drugs have been used in super-refractory SE with variable outcomes. Conclusion: Over the past 25 years major advances in definition, classification and understanding of its mechanisms have been achieved. Despite this up to 40% of patients in early status cannot be controlled with first line drugs. The treatment of super-refractory status is still an almost evidence free zone.
Introduction
Status epilepticus has an estimated incidence of up to 61 episodes per 100,000 per year and an overall mortality of 20% (range 1.9-40%) [1, 2] . There has been considerable development in the past 25 years in the understanding of its pathophysiology, causes, clinical features, EEG changes, prognosis and treatment [3, 4] . The purpose of this narrative review in the 25-year anniversary issue of "Seizure-The European Epilepsy Journal" is to give an update on definition, classification and therapeutic options for patients in SE.
Recent advances in the definition and classification of status epilepticus
Status epilepticus is often referred to the "maximum expression of epilepsy", but status is also a severe expression of an acute brain insult or systemic disturbance, which leads to excessive hyperexcitation of nervous tissue. The modern definition and classification of status epilepticus has its roots back to the 10th Marseilles Colloquium (the 10th European Electroencephalographic Meeting) in 1962, which was completely devoted to status epilepticus. Gastaut and co-workers proposed a definition, which was consistent with the meaning of the original term status in Latin: "Status epilepticus is a term whenever a seizure that persists for a sufficient length of time or is repeated frequently enough to produce a fixed and enduring condition" [5] [6] [7] . Although there was no duration specified in the definition, Gastaut later proposed 60 min to define status epilepticus [8] . In the revision of 1981, the definition was minimally changed into a "seizure" that "persists for a sufficient length of time or is repeated frequently enough that recovery between attacks does not occur." [9] . Status was classified under the terms "prolonged or repetitive seizures (status epilepticus)"and was divided into partial (e.g., Jacksonian), or generalized (e.g., absence status or tonic-clonic status). "When very localized motor status occurs, it is referred to as epilepsia partialis continua". These concepts, while highly valuable, were imprecise, as they did not define the duration of a seizure that was fixed and enduring "or" sufficient length. In the past, experts suggested that 30 min of ongoing seizure activity could be regarded as "fixed and enduring". Over the past two decades the timelines in clinical trials and treatment recommendations were progressively moved to 20 min [10] and to 10 min [11] . Lowenstein et al. suggested in 1999 that a generalized tonic clonic seizure that is longer than the usual two to three minutes is prolonged, and should be treated as SE [12] . The time limit for convulsive status was consequently set to 5 min, which opened the door to change our view on the classical definitions of SE. The Commission of Classification and Terminology of the International League Against Epilepsy and the Commission on Epidemiology charged a Task Force with clinical researchers and epidemiologists to revise the classification of status epilepticus in 2009. The Task force came out in 2015 with the following definition: "Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally prolonged seizures (after time point t1). It is a condition, which can have long-term consequences (after time point t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures" [13] . This new definition of SE gives a good guidance, when emergency treatment must be considered. In general, time point t1 is the time when treatment should be started, which is at 5 min for generalized tonic clonic seizures, and at 10 min for focal seizures with or without impairment of consciousness. Time-point t2 marks the time at which neuronal damage or self-perpetuating alteration of neuronal networks may begin, and indicates that SE should be controlled latest by that time; 30 min in case of generalized tonic clonic seizures (Fig. 1) .
The task force also came out with a new classification, built on four axes [13] : (i) semiology, (ii) etiology, (iii) EEG correlates, and (iv) age. The backbone of the classification is the semiology. The various clinical forms of status epilepticus are differentiated along two taxonomic criteria: motor activity and impairment of consciousness falling into two major groups: [1] status epilepticus with prominent motor symptoms, including all convulsive forms, and [2] those without prominent motor symptoms representing the non-convulsive forms of status epilepticus (NCSE) (see Table 1 ). Each group can be divided again according to the degree of impairment of consciousness, which is highly clinically relevant. Comatose NCSE represents a life threatening condition that requires urgent and consequent treatment, whereas NCSE proper without coma occurs most often in the form of absence status or focal status with impairment of consciousness (older terms for this conditions were "psychomotor status" or "complex partial status epilepticus") [13, 14] . The etiology of status is divided into two groups: (i) known or symptomatic and (ii) unknown or cryptogenic. The symptomatic group can be subdivided into acute symptomatic, remote symptomatic and progressive symptomatic. The new classification also provides a list of known causes of status as an appendix to the classification, which can be updated periodically as new information emerges. Status epilepticus often occurs in the context of genetic epilepsy syndromes, but there is always a trigger for the status itself, such as fever, electrolyte disturbance or other intrinsic factors [15] .
The third axis of the classification comprises EEG correlates of status. In convulsive SE the clinical presentation is most often clear and artefacts obscure the EEG, thus the EEG is of little value. The opposite is true for the non-convulsive forms of status epilepticus, where a correct diagnosis is often not possible without EEG. In the Table 1 Axis 1 of the classification of status epilepticus (SE) [13] . most extreme forms the patient is in deep coma, and only an EEG can reveal the epileptiform or rhythmic discharges leading to the diagnosis [14, 16] . The task force recommends describing the EEG correlate of status in a patient using the following descriptors: name of pattern, morphology, location, time-related features, modulation, and effect of intervention, and use the recently proposed terminology by the American Clinical Neurophysiology Society [17] and the diagnostic "Salzburg EEG criteria for NCSE" (Table 2 ) [16, [18] [19] [20] as a practical guide for diagnosis. In a recent retrospective diagnostic accuracy study using EEG recordings from patients admitted for neurological symptoms or signs of NCSE to three centers (Danish Epilepsy Centre, Dianalund, Denmark; Aarhus University Hospital, Aarhus, Denmark; and Paracelsus Medical University, Salzburg, Austria) in two countries (Austria and Denmark) confirmed the high clinical utility for the "Salzburg EEG criteria for NCSE" [21] . The sensitivity was 97.7% (95% CI 87.9-99.6) and specificity was 89.6% (95% CI 80.8-94.6); overall accuracy was 92.5% (95% CI 88.3-97.5). The positive predictive value was 84.0% (95% CI 74.1-91.5) and negative predictive value was 98.6% (95% CI 94.4-100).
The new classification underwent a feasibility study: 488 episodes of status epilepticus were retrospectively assessed and classified according to the clinical tradition and the new classification. 230 (47%) had a generalized convulsive, and 29 (6%) had a nonconvulsive SE in coma; both categories overlapped almost perfectly between the two classifications. However in focal SE, which was markedly heterogeneous, the new classification appears to better reflect the clinical reality, offering more relevant subdivisions, which also differ in mortality rates [22] .
Recent advances in the treatment of status epilepticus
The management of status epilepticus and its pharmacological treatment still represents an area with limited evidence derived from high-quality, adequately powered randomized controlled trials (RCTs) to inform clinical practise. However, there have been clear advances in the understanding of the pathomechanisms, which have led to more effective treatment strategies. The therapeutic principle "time is brain" applies not only for stroke but also for status epilepticus, as the prognosis of SE worsens with increasing duration of seizure activity [23, 24] . Indeed, prompt recognition and earliest treatment of status epilepticus is associated with lower morbidity and mortality, fewer drugs required in hospitals, and reduction in seizure duration [25, 26] . The cost of status in the refractory stages are high and a recent study in Germany has estimated s1,365/day [27] . Nevertheless, there is only limited industry interest to develop new treatments to prevent refractory status.
Until late 1980s there was large variation in patient stabilization procedures, laboratory measures, and sequence of medications in the management of SE [28] . In the year 1993, the Epilepsy Foundation of America convened a working group on SE. They published guidelines and a treatment protocol [10] , which was based on a literature review and input from experts. Some key treatment principles of this guideline still remain valid. All treatment protocols recognize a staged approach to treatment with different drugs used in early (stage I), established (stage II), refractory (stage III) and super-refractory SE (stage IV) (Fig. 2) and emphasize prompt recognition and treatment of persisting seizure activity at each stage aiming to reduce morbidity, mortality, and long-term consequences of status epilepticus (beyond t2). Most recent reviews focus on the pharmacotherapy of status, but general measures of neurological emergencies and a thorough search for the causes are equally important [29] [30] [31] .
Most clinical trials have been performed in the early stages of status epilepticus, which has been the subject of several RCTs and critical assessment in systematic reviews with meta-analyses [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] and included in treatment protocols or practical guidelines [29] [30] [31] 45, 46] .
The most effective treatment of early status epilepticus is intravenous benzodiazepines, which are able to control status promptly in about two thirds of all patients [3, 42] . Benzodiazepines exert their antiepileptic properties by enhancing the inhibitory neurotransmission through increasing channel opening frequency of the GABA-A receptors, with subsequent increased chloride conductance and neuronal hyperpolarization [47] . The benzodiazepines commonly used as first-treatment in SE are lorazepam, diazepam, midazolam and clonazepam (Fig. 3) . Intravenous lorazepam is less lipid-soluble (octanol/water partition coefficient for lorazepam is 73 [48] ) and hence does not undergo a Table 2 Salzburg EEG consensus criteria for nonconvulsive status epilepticus [18, 20, 21] .
rapid redistribution into peripheral tissues as diazepam, which should also result in a clinical longer duration of action [47, 49] . Previous meta-analyses [33] of all randomized controlled studies [50] [51] [52] found lorazepam to be superior. Since the Cochrane Review another large trial was performed in children with status epilepticus (273 patients; 140 randomized to diazepam and 133 to lorazepam), which failed to show a superiority of lorazepam in terms of seizure control [53] . Moreover in this study children who received lorazepam were more often sedated. In a recent systematic review with meta-analysis of randomized controlled trials five RCTs were included, with a total of 656 patients, 320 randomly allocated to IV LZP and 336 to IV DZP. No statistically significant differences were found between IV LZP and IV DZP for clinical seizure cessation (RR 1.09; 95% CI 1.00-1.20), continuation of SE requiring a different drug (RR 0.76; 95% CI 0.57-1.02), seizure cessation after a single dose of medication (RR 0.96; 95% CI 0.85-1.08), need for ventilator support RR 0.93; 95% CI 0.61-1.43, and clinically relevant hypotension [40] . The authors concluded consequently "Despite its favorable pharmacokinetic profile, a systematic appraisal of the literature does not provide evidence to strongly support the preferential use of IV LZP as first-line treatment of convulsive SE over IV DZP". An overview on the staged treatment approach is given in Fig. 3 .
In the past decades alternative routes of administrations have been explored. A landmark study intramuscular midazolam was compared to intravenous lorazepam as first-line treatment for convulsive status epilepticus in a double blind, randomized, noninferiority design. This study included 893 children and adults treated by paramedics before admission to hospital [26] . Seizures were controlled in 73.4% with intramuscular midazolam, and in 63.4% with intravenous lorazepam (absolute difference 10%; 95% CI: 4.0 to 16.1%; p < 0.001 for both non inferiority and superiority). Among patients whose seizures ceased before arrival to the emergency department, the median time to drug administration was significantly shorter in the midazolam group (1.2 min vs 4.8 min), although clinical seizure cessation occurred earlier after lorazepam administration (1.6 min vs. 3.3 min) [26] .
Intranasal and buccal administration of benzodiazepines have been studied extensively over the past years. The water-soluble midazolam offers pharmacological advantages over the lipophilic lorazepam and diazepam. In a comprehensive meta-analysis the efficacy and safety of non-intravenous midazolam in adults and children were compared to rectal or intravenous diazepam. Nineteen studies with 1933 seizures in 1602 patients were included. For seizure cessation, non-IV midazolam was as effective as diazepam (any route) (1933 seizures; RR: 1.03; 95% CIs: 0.98-1.08). No difference in adverse effects was found between non-IM midazolam and diazepam by any route (1933 seizures; RR: 0.87; 95% CIs: 0.50-1.50) [35] . A common reference based meta-analysis compared intranasal to buccal administration midazolam [34] . Intravenous or rectal diazepam or intravenous lorazepam served as the reference for indirect comparisons. The authors did not find a difference in efficacy between intranasal and buccal midazolam, but found a large width and asymmetrical distribution of confidence intervals around the obtained OR of 2.81 (95% CI 0.39-20.12) comparing intranasal midazolam with rectal diazepam for serious adverse effects [34] . However, overall, these data indicate that midazolam administered by non-intravenous routes represents a practical, rapid, reasonably safe and effective alternative to either intravenous lorazepam or intravenous/rectal diazepam as first-line treatment of early status epilepticus in out of hospital settings (Fig. 4) .
Approximately 40% of patients with generalized convulsive SE (GCSE) are refractory to benzodiazepine treatment [11, 26, 52] . This ongoing seizure activity is referred to as established SE (or stage II). In established SE, intravenous antiepileptic drugs (phenytoin/ fosphenytoin, valproate, levetiracetam, phenobarbital, and lacosamide) are most commonly used, but there is no class I evidence for choosing one over the other. This unsatisfactory situation has several consequences: firstly most patients are treated off label. Recent data from a registry in Germany, Austria, and Switzerland [54] and a global audit [55] suggests that 34% of patients in the early stages and 91% in the later stages receive off label treatment. Secondly, status epilepticus, with its high mortality and severe morbidity is a shaky ground for the pharma industry to embark in high-class trials with unknown return of investments. And thirdly, there are no well-defined regulatory pathways for drugs to treat later stages of status epilepticus. This leaves the clinicians uninformed about the best choice in the established stage of status epilepticus and they have to take decisions under uncertainty, with all the medico-legal consequences. Guidelines, which are based on currently available evidence are only a weak remedy, because the evidence they are based on is weak. There are several comprehensive narrative reviews on the pharmacologic treatment of status [3, 42, 43] (Fig. 3) . Currently a large NIH funded trial (Established Status Epilepticus Trial, ESET) is on the way, which is designed as a multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the emergency department treatment of patients with benzodiazepine-refractory status epilepticus [ClinicalTrials.gov Identifier: NCT01960075] [56, 57] . The trial is currently recruiting and first results can be expected in 2017. Until the results of this trial are available, newer drugs such as lacosamide will be used extensively in established and refractory status epilepticus [58, 59] .
In a review of 136 patients with refractory SE (50% nonconvulsive SE, 31% focal SE, and 19% convulsive SE) treated with lacosamide an overall success rate of 56% was reported with adverse events observed in 25% (mostly mild sedation) [59] . These findings have been confirmed by a subsequent cohort study [60] and by a case series conducted in 55 patients with SE and 43 patients with acute repetitive seizures [61] . The most commonly used bolus dose was 400 mg, followed by a daily dose of 200-400 mg lacosamide leading to abrogation of seizures in 56% (76/136) [59] . Intravenous brivaracetam is already on the market and experts feel that there is a certain potential for this drug in status epilepticus, but so far no reports in humans have been published.
In 31-43% of patients in established status epilepticus are not controlled with antiepileptic drugs [62, 63] . In this stage, also called refractory status epilepticus, intravenous anesthetic drugs (thiopental/pentobarbital, midazolam, or propofol) have been, and still are, commonly used in the past 30 years (Fig. 3) . In a global audit of 488 episodes of RSE, continuous midazolam infusion was the most widely used anesthetic in (59%) followed by propofol (32%) and barbiturates (8%) [55] . In two systemic reviews none of the treatments currently available was superior to another [64, 65] . Propofol may be associated with metabolic acidosis, rhabdomyolysis, renal failure and heart failure [66] . This propofol infusion syndrome occurs less likely, when treatment duration is less than 48 h and doses does not exceed 5 mg/kg/h. Midazolam seems to be the safest drug at this stage with the lowest rate of cardiovascular and metabolic complication, while barbiturates seem to be most often associated with cardiovascular complications, severe immunosuppression, and infections in the [64, 65] . The use of anesthetics in refractory and super-refractory SE was associated with more infections during status epilepticus (43% vs 11%; p < 0.0001) and a 2.9-fold relative risk for death (2.88; 95% confidence interval 1.45-5.73) in a 6-year prospective cohort study including 171 patients (63 of them received intravenous anesthetics) [67] .
These findings fueled the search for more efficacious and better tolerated treatments in refractory and super-refractory status. Ketamine has gained much interest, due to its pharmacological properties. Its strong antagonistic effect on the N-methyl-Daspartate (NMDA) -glutamate receptors [68] , which play a key role in the advanced forms of status epilepticus [69] [70] [71] . There are three retrospective case series to date [72] [73] [74] and 10 case reports [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] reporting 94 episodes of refractory status epilepticus in adults treated with ketamine leading to successful termination of status epilepticus in 63% [43] . Ketamine is a racemic mixture containing equal amounts of two enantiomers, (S)-and (R)-ketamine. Ketamine is extensively metabolized by N-demethylation producing norketamine, a non-competitive NMDA receptor antagonist that may also exhibit enantioselective pharmacological activity. (S)-Ketamine has different pharmacodynamic activities and is a two to threefold more potent analgesic agent than (R)-ketamine. (S)-Ketamine administered alone has a higher clearance than in the racemic mixture resulting in quicker elimination, shorter duration of action and a faster recovery from anesthesia [85] . The S-enantiomer was also associated with a more rapid recovery of psychomotor skills than the racemic mixture [86] . Thus the use of (s)-ketamine in refractory and super-refractory status should have clinically relevant advantages. One large single center study from Austria reported on 42 patients who were treated with (s)-ketamine. The median duration of status epilepticus was 10 days; the median latency from SE onset to the first administration of (s)-ketamine was 3 days. In 64% of patients (s)-ketamine was the last drug before cessation of status. However, in five patients, it was given with propofol at the same time, so a definite causal inference could not be drawn. Median duration of administration was 4 days. Overall (s)-ketamine treatment was well tolerated, adverse effects were not observed, and overall mortality was 45.2% [87] .
The new antiepileptic drug perampanel also exerts its mechanism on the antiglutamatergic pathways. Unlike ketamine it does not act, even at high doses on the NMDA receptors, but is a non-competitive antagonist at the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor [88, 89] . Perampanel was administered via nasogastric tube in 22 cases. The initial median dose was 4 mg, which was uptitrated to median 12 mg [90] [91] [92] . The patient numbers in these case series are low (largest single center experience with 12 cases) and patients too heterogeneous to draw valid conclusions on efficacy.
Another new strategy in the treatment of super-refractory status epilepticus involved neurosteroid. As status evolves over time, synaptic GABA-A receptors are internalized from the synaptic membrane to the cytosol leading to a lack of efficacy of benzodiazepines in later stages of SE, while extrasynaptic GABA-A receptors do not undergo internalization [93, 94] . The neuroactive steroid allopregnanolon acts as a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors [95] . In animal models the efficacy of allopregnanolon in cessation of established SE was observed. The evidence in humans is limited to only three patients (one adult, two children) with super-refractory SE reported to date. In all reported cases, allopregnanolon led to control of SE allowing the general anesthetics to be weaned [96] . Following successful completion of a phase I/II study (ClinicalTrials.gov Identifier: NCT02052739; results not in the public domain) in superrefractory status epilepticus, an US based company is currently conducting a large multicenter phase III trial with the neuroactive steroid (ClinicalTrials.gov Identifier: NCT02477618). The aims of the trial are very ambitious and irrespective, whether the trial meets the endpoint, important data on the causes, clinical presentations and EEG in superrefractory status will be gathered.
Other treatments than the intravenous anesthetics (thiopental, pentobarbital, midazolam, propofol, ketamine,) including nonpharmacologic therapies were used in this stage of status epilepticus (inhalational anesthetics, topiramate, lacosamide, pregabaline, levetiracetam, magnesium, pyridoxine, immunotherapy) and non-pharmacological treatments (hypothermia, ketogenic diet, emergency neurosurgery, electroconvulsive therapy, cerebrospinal fluid drainage, vagal nerve stimulation and deep brain stimulation) [65] . Ferlisi and Shorvon have reviewed these treatments and their outcomes [65, 97] .
There is growing evidence of inflammation as an important factor in epileptogenesis, as well as the increasing discovery of antibodies against neural targets as underlying cause of some forms of encephalopathies presenting with seizures and refractory status epilepticus [98] . Therefore, anti-inflammatory agents like steroids and immunoglobulines as well as plasma exchange in super-refractory SE becomes more frequent despite any evidence supporting its use without a proven or suspected underlying immunological disorder [97] . There are potential side effects associated with immunosuppression, such as severe infections and metabolic disturbances, which are to be taken into account when a trial with anti-inflammatory drugs in super-refractory SE is considered. The recently published clinical algorithm is helpful in making the decision for a potentially harmful treatment [99] .
Conclusion
There have been major advances in the clinical field with a new definition and classification, which gives clinicians a better guidance as to when to treat, how aggressive to treat, and how to avoid over-or under-treatment of this condition. In the treatment arena new small companies embark in the development of niche products, such as neurosteroids in super refractory status epilepticus or new alternative methods of application. The increased interest in status epilepticus has alerted clinicians to treat early and more appropriate and search consequently for the causes of status in each patient. Despite these achievements there are many unmet needs, beginning with identification of cause directed treatments not only to prevent status recurrence but also to protect the brain from the consequences of status and the development of epilepsy to the better delineation of the subtypes of status. This can only be achieved through better understanding of the mechanisms of status in different causes and major efforts to bridge the gap between preclinical knowledge to human applications.
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